The aim. To establish the prevalence of PMS symptoms and evaluate the medication management of this disorder in Lviv.Materials and methods. The objects of the study were: scientific publications related to the problem of PMS; the results (n=105) of the survey. Methods applied: systematization, generalization, comparison, questionnaire. The statistical analyses (descriptive statistics, univariable analysis using simple logistic regression, multiple logistic regression) were performed with SPSS Trial.Results. The prevalence of PMS among the surveyed was high (83.8 %). The most common complaints are abdom-inal and/or low back pain (46.6 %) and increased irritability/aggression (43.2 %). Almost half (46.6 %) of women who experienced PMS consult a pharmacist, and only 23.9 % seek medical advice. At the same time, 87.5 % (n=77) of women (among those suffering from PMS) use medicines to alleviate/eliminate the symptoms of PMS. Nonste-roidal anti-inflammatory drugs (77.6 %), sedatives (36.8 %), and complex herbal remedies that affect the genital system (18.4 %) are the most common drugs for PMS.Choosing the way of PMS management, 44.8 % of women would prefer herbal medicines to synthetic ones. Both previous using of synthetic drugs for PMS and adverse drug reactions to synthetic drugs have a statistically signif-icant contribution to a positive attitude towards herbal remedies (p=0.004 and p=0.026, respectively).Conclusion. PMS is a common medical and social issue. Achieving effective and safe medication management of PMS requires the joint participation of a physician, pharmacist, and the patient in terms of compliance and lifestyle adjustments.
Спазмолітики – широковживана група безрецептурних лікарських засобів (ЛЗ), що застосовуються для самолікування симптомів спастичного болю. Серед спазмолітиків найпопулярнішим є дротаверин. Варто зазначити, що дротаверин зареєстрований у близько 50-ти країнах світу, включаючи Центральну, Східну Європу та Азію. У той же час, через небезпеку передозування та летальної кардіотоксичності у країнах Західної Європи та США застосування препарату заборонено